Total neoadjuvant therapy: Fact, fantasy, or fallacy?
Source : https://www.sciencedirect.com/science/article/abs/pii/S0960740422000317?via=ihub
Colorectal cancer is the second leading cause of cancer death in the United States for men and women, with an estimated 146,000 new cases per year - a staggering 53,000...
Conclusion/Relevance: Over the past few years, with rectal cancer death rates exceeding 30% from metastatic disease, growing interest focused on the attributes of induction chemotherapy to eradicate minimal residual disease and purportedly increase survival. This led to the development of Total Neoadjuvant Therapy. We now have high-quality data...
Application of Anesthetics in Cancer Patients: Reviewing Current Existing Link With Tumor Recurrence - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35296017/
Surgery remains the most effective cancer treatment, but residual disease in the form of scattered micro-metastases and tumor cells is usually unavoidable. Whether minimal residual disease results in clinical metastases...
Conclusion: Whether minimal residual disease results in clinical metastases is a function of host defense and tumor survival and growth. The much interesting intersection of anesthesiology and immunology has drawn increasing clinical interest, particularly, the existing concern of the possibility that the perioperative and intraoperative...
The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35267616/
The study of cell-free DNA (cfDNA) and other peripheral blood components (known as "liquid biopsies") is promising, and has been investigated especially in solid tumors. Nevertheless, it is increasingly showing...
Conclusion: This review focuses on the clinical applications of cfDNA on the minimal residual disease in hematological malignancies.
High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35271751/
Minimal residual disease (MRD) constitutes the most important prognostic factor in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Flow cytometry is widely used in MRD assessment, yet little is known regarding...
Relevance: The present work is the first to demonstrate a CD34 negative immunophenotype as a good prognostic factor in ALL, whereas high CD34 expression associates with poor therapy response and an altered gene expression profile reminiscent of migrating cancer stem-like cells.
NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia - Purinergic Signalling
Source : https://link.springer.com/article/10.1007/s11302-022-09841-x
The risk stratification of B-acute lymphoblastic leukemia (B-ALL) is based on clinical and biological factors. However, B-ALL has significant biological and clinical heterogeneity and 50% of B-ALL patients do not...
Conclusion/Relevance: “In univariate analyses, expression of NT5E was significantly associated with worse progression-free survival (PFS) in bone marrow (BM) samples. In multivariate analyses, Kaplan–Meier analysis, and log-rank test, higher NT5E expression predicted unfavorable PFS in BM samples. Considering minimal residual disease (MRD),...